Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy - PubMed (original) (raw)

Comparative Study

doi: 10.1536/ihj.46.231.

Affiliations

• PMID: 15876807
• DOI: 10.1536/ihj.46.231

Free article

Comparative Study

Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy

Kan Zen et al. Int Heart J. 2005 Mar.

Free article

Abstract

We examined the plasma levels of soluble Fas (sFas) or Fas ligand (sFas-L), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in patients with idiopathic nonobstructive (HNCM) and dilated-phase (DHCM) hypertrophic cardiomyopathy. Patients with idiopathic hypertrophic cardiomyopathy (HCM) may deteriorate to DHCM and the pathogenesis is unknown. The levels of these plasma cytokines were measured by ELISA and echocardiography was performed in 38 HNCM and 11 DHCM patients, and 10 normal subjects. The follow-up period was three years. In HNCM, TNF-alpha (43.3 +/- 45.2 versus 16.9 +/- 4.3 pg/mL) and IL-6 (65.1 +/- 86.4 versus 4.0 +/- 2.1 pg/mL) were slightly higher compared to normal subjects and sFas (3.7 +/- 1.2 versus 2.1 +/- 0.7 ng/mL) increased significantly. sFas (3.9 +/- 1.8), TNF-alpha (79.3 +/- 72.4), and IL-6 (234.1 +/- 135.2) in DHCM were significantly increased and only IL-6 was significantly different from HNCM. sFas-L (0.18 +/- 0.08 versus 0.25 +/- 0.05 ng/mL) in HNCM was significantly decreased, and the decrease was marked in DHCM (0.05 +/- 0.02). In HNCM, TNF-alpha was negatively correlated with fractional shortening (r = -0.432, P = 0.0062) or positively with IL-6 (r = 0.665, P < 0.0001), while sFas-L was negatively correlated with IL-6 (r = -0.580, P < 0.0001). DHCM with high sFas had significantly higher cumulative incidences of worsening heart failure. The Fas/Fas-L system and proinflammatory cytokines may play an important role in the status of HCM and its progression to DHCM.

PubMed Disclaimer

Similar articles

• Comparative study of the roles of cytokines and apoptosis in dilated and hypertrophic cardiomyopathies.
  Buzás K, Megyeri K, Hõgye M, Csanády M, Bogáts G, Mándi Y. Buzás K, et al. Eur Cytokine Netw. 2004 Jan-Mar;15(1):53-9. Eur Cytokine Netw. 2004. PMID: 15217753
• Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
  Nishigaki K, Minatoguchi S, Seishima M, Asano K, Noda T, Yasuda N, Sano H, Kumada H, Takemura M, Noma A, Tanaka T, Watanabe S, Fujiwara H. Nishigaki K, et al. J Am Coll Cardiol. 1997 May;29(6):1214-20. doi: 10.1016/s0735-1097(97)00055-7. J Am Coll Cardiol. 1997. PMID: 9137215
• Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure.
  Adamopoulos S, Parissis J, Karatzas D, Kroupis C, Georgiadis M, Karavolias G, Paraskevaidis J, Koniavitou K, Coats AJ, Kremastinos DT. Adamopoulos S, et al. J Am Coll Cardiol. 2002 Feb 20;39(4):653-63. doi: 10.1016/s0735-1097(01)01795-8. J Am Coll Cardiol. 2002. PMID: 11849865 Clinical Trial.
• Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure.
  Kinugawa T, Kato M, Yamamoto K, Hisatome I, Nohara R. Kinugawa T, et al. Int Heart J. 2012;53(3):182-6. doi: 10.1536/ihj.53.182. Int Heart J. 2012. PMID: 22790687
• [Dilated form of hypertrophic cardiomyopathy].
  Yamada A, Suzuki H, Kawai S. Yamada A, et al. Nihon Rinsho. 2000 Jan;58(1):102-7. Nihon Rinsho. 2000. PMID: 10885296 Review. Japanese.

Cited by

• Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy.
  Fragkiadakis K, Ktena N, Kalantidou A, Dermitzaki E, Anastasiou I, Papathanassiou S, Kontaraki J, Kalomoirakis P, Kanoupakis E, Patrianakos A, Papadomanolakis A, Daskalaki E, Kiousi T, Kouraki K, Kranioti E, Tzardi M, Venihaki M, Karagogeos D, Capetanaki Y, Kardassis D, Kochiadakis G, Parthenakis F, Marketou M. Fragkiadakis K, et al. Cells. 2024 Aug 9;13(16):1328. doi: 10.3390/cells13161328. Cells. 2024. PMID: 39195218 Free PMC article.
• The Immune and Inflammatory Basis of Acquired Pediatric Cardiac Disease.
  Jui E, Singampalli KL, Shani K, Ning Y, Connell JP, Birla RK, Bollyky PL, Caldarone CA, Keswani SG, Grande-Allen KJ. Jui E, et al. Front Cardiovasc Med. 2021 Jul 27;8:701224. doi: 10.3389/fcvm.2021.701224. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34386532 Free PMC article. Review.
• Intervention for apoptosis in cardiomyopathy.
  Yaoita H, Maruyama Y. Yaoita H, et al. Heart Fail Rev. 2008 Jun;13(2):181-91. doi: 10.1007/s10741-007-9074-6. Heart Fail Rev. 2008. PMID: 18080184 Review.
• Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Cats With Hypertrophic Cardiomyopathy.
  Fries RC, Kadotani S, Stack JP, Kruckman L, Wallace G. Fries RC, et al. Front Vet Sci. 2022 Mar 14;9:813524. doi: 10.3389/fvets.2022.813524. eCollection 2022. Front Vet Sci. 2022. PMID: 35359679 Free PMC article.
• Cardiac Biomarkers in Sports Cardiology.
  Costache AD, Leon-Constantin MM, Roca M, Maștaleru A, Anghel RC, Zota IM, Drugescu A, Costache II, Chetran A, Moisă ȘM, Huzum B, Mitu O, Cumpăt C, Honceriu C, Mitu F. Costache AD, et al. J Cardiovasc Dev Dis. 2022 Dec 11;9(12):453. doi: 10.3390/jcdd9120453. J Cardiovasc Dev Dis. 2022. PMID: 36547450 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • J-STAGE, Japan Science and Technology Information Aggregator, Electronic

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal